Search
Research
Children’s regenerative and genetic medicine programThe project aims to build capacity in regenerative medicine for children with respiratory diseases.
Research
Epithelial Drivers of Neutrophil Plasticity in Early Cystic Fibrosis Lung DiseaseHallmarks of cystic fibrosis (CF) airway disease include bronchiectasis, airway inflammation by infiltrating polymorphonuclear neutrophils (PMNs) and recurring infection.
Research
WA Epithelial Research Program for Childhood Respiratory DiseasesOnce thought to be a simple barrier to the external environment, epithelial cells are involved in many repair and inflammatory processes that occur in childhood airway diseases.
Research
Mechanisms of Acute Viral Respiratory Illness in Children (MAVRIC)Large numbers of children need emergency medical treatment each year for respiratory illnesses, particularly for wheezing and asthma.
Research
Azithromycin mitigates human rhinovirus impact on barrier integrity and function in non-diseased airway epitheliumAzithromycin improves symptomology in various chronic airway diseases exacerbated by viral infections. However, the mechanisms underlying the apparent antiviral effects of azithromycin remain unclear.
Research
Murine bone-derived mesenchymal stem cells undergo molecular changes after a single passage in cultureThe rarity of the mesenchymal stem cell (MSC) population poses a significant challenge for MSC research. Therefore, these cells are often expanded in vitro, prior to use. However, long-term culture has been shown to alter primary MSC properties.
Research
Lessons learnt from influenza vaccination in immunocompromised children undergoing treatment for cancerInfluenza infection contributes substantially to global morbidity and mortality, with children undergoing treatment for cancer among the most vulnerable due to immunosuppression associated with disease and treatment. However, influenza remains one of the most common vaccine-preventable diseases.
Research
Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocolThe outcome of infants with KMT2A-germline acute lymphoblastic leukaemia (ALL) is superior to that of infants with KMT2A-rearranged ALL but has been inferior to non-infant ALL patients. Here, we describe the outcome and prognostic factors for 167 infants with KMT2A-germline ALL enrolled in the Interfant-06 study.
Research
Invasive fungal disease in children with acute myeloid leukaemia: An Australian multicentre 10-year reviewInvasive fungal disease (IFD) is a common and important complication in children with acute myeloid leukaemia (AML). We describe the epidemiology of IFD in a large multicentre cohort of children with AML.
Research
Outcomes for Australian children with relapsed/refractory acute lymphoblastic leukaemia treated with blinatumomabWe report on the Australian experience of blinatumomab for treatment of 24 children with relapsed/refractory precursor B-cell acute lymphoblastic leukaemia (B-ALL) and high-risk genetics, resulting in a minimal residual disease (MRD) response rate of 58%, 2-year progression-free survival (PFS) of 39% and 2-year overall survival of 63%. In total, 83% (n = 20/24) proceeded to haematopoietic stem cell transplant, directly after blinatumomab (n = 12) or following additional salvage therapy (n = 8).